Novartis Investigative Site

Sunto-gun, Shizuoka 4118777

0 studies enrolling now · 11 studies all time

What they study most

Acute Myeloid Leukemia (AML), Colorectal Cancer, Diffuse Large B-cell Lymphoma, Gastroesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Metastatic Renal Cell Carcinoma, Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL), Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Solid Tumors

Studies at this site

• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects — Stopped early
• Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers — Completed
• VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) — Stopped early
• Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies — Stopped early
• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors — Stopped early
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A — Stopped early
• LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer — Completed
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy — Completed
• LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib — Completed
• A Study of Nilotinib Versus Imatinib in GIST Patients — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed